Highlights

  • Third quarter 2026 revenue was $209.3 million, compared with $188.8 million, an increase of 11% as reported and 12.5% organic.
  • GAAP loss per diluted share was $0.68 in the quarter, including a $41,242 thousand intangible asset impairment charge, against earnings of $0.26.
  • Adjusted earnings per diluted share, a non-GAAP measure, were $0.53 in the third quarter, compared with $0.46 a year earlier.
  • Full year 2026 revenue guidance was updated to $844M to $852M, including BioLife Solutions from its October 6, 2026 closing date.

Repligen Corporation (NASDAQ: RGEN) shares were trading at USD 173.80 on October 27, 2026, down 3.54%, with a relative volume at time of 2.82. The bioprocessing company closed its acquisition of BioLife Solutions on October 6, opened a training center in Seoul on October 23, and reported third quarter 2026 results with updated full year guidance on October 27.

Repligen is incorporated in Delaware and lists its principal executive offices in Waltham, Massachusetts. It is a global bioprocessing company that develops and commercializes technologies and integrated solutions supporting steps in the manufacturing and delivery of biologic drugs. Its customers include biopharmaceutical developers, manufacturers and contract development and manufacturing organizations. Management discusses results by franchise, including filtration, chromatography, proteins and analytics.

Third Quarter 2026 Results

Repligen reported revenue of $209.3 million for the three months ended September 30, 2026, compared with $188.8 million a year earlier. The company described this as an increase of 11% as reported and 12.5% organic. Total revenue for the nine months was $607,697 thousand, compared with $540,343 thousand.

On a GAAP basis, the company reported a loss from operations of $29.5 million, compared with income from operations of $16.8 million. The company attributed the loss primarily to an intangible asset impairment charge of $41,242 thousand. Management said on the call that the charge relates to an intellectual property license agreement and is not included in adjusted results.

The net loss was $38,432 thousand, compared with net income of $14,911 thousand a year earlier. Loss per diluted share was $0.68, compared with earnings per share of $0.26. For the nine months, the net loss was $25,091 thousand, or $0.44 per share, compared with net income of $35,607 thousand, or $0.63.

GAAP gross margin was 53.0%, compared with 53.2%.

Adjusted Results

All adjusted figures are non-GAAP. Adjusted income from operations was $33.3 million, compared with $26.8 million. Adjusted earnings per diluted share were $0.53, compared with $0.46. The adjusted operating margin was 15.9%, compared with 14.2%.

Balance Sheet and Cash Flow

Cash, cash equivalents and marketable securities were $863 million at September 30, 2026, compared with $768 million at December 31, 2025. Convertible Senior Notes due 2028, net, were $555,596 thousand, compared with $542,213 thousand.

Cash provided by operating activities for the nine months was $104,160 thousand, compared with $91,713 thousand. The CFO said on the call that the company deployed approximately $550 million of cash, including fees and net of cash received, for the BioLife transaction in October, and that pro forma cash is currently greater than $300 million.

Developments and 2026 Outlook

The company said the BioLife acquisition adds a consumables platform in cell therapy. Management said it has taken actions to realize a portion of its expected operating expense synergies, and that it expects BioLife to be slightly dilutive to fourth quarter adjusted earnings per share and to deliver at least $0.05 of accretion in 2027.

Repligen's current guidance, given on October 27, 2026, is adjusted and non-GAAP. It includes the expected impact of BioLife from the October 6, 2026 closing date and excludes any other potential business acquisitions and future foreign currency fluctuations.

  • Total reported revenue: $844M to $852M, with reported growth of 14.5% to 15.5% and organic growth of 12% to 13%.
  • Income from operations: $135M to $139M, with an operating margin of 16.0% to 16.3%.
  • Net income: $119M to $122M, with diluted earnings per share of $2.05 to $2.09.

The company also expects other income of about $18M and a tax rate of about 22%. Management said capital expenditures are expected to be 3% to 4% of 2026 revenue. It said its 2027 comments are not formal guidance, and that it expects reported revenue growth of at least 25% in 2027 if foreign exchange rates do not change materially.